Skip to content
Deslanoside
Cedilanid (deslanoside) is a small molecule pharmaceutical. Deslanoside was first approved as Cedilanid-d on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, heart failure, low cardiac output, and supraventricular tachycardia in the USA. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deslanoside
Tradename
Company
Number
Date
Products
CEDILANID-DNovartisN-009282 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
heart failureEFO_0003144D006333I50
low cardiac output—D002303—
supraventricular tachycardiaHP_0004755D013617I47.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01A: Cardiac glycosides
— C01AA: Digitalis glycosides
— C01AA07: Deslanoside
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDESLANOSIDE
INNdeslanoside
Description
Deslanoside is a cardenolide glycoside that is lanatoside C with the acetoxy group replaced by a hydroxy group. It has a role as an anti-arrhythmia drug, a cardiotonic drug, a metabolite and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a 14beta-hydroxy steroid, a 12beta-hydroxy steroid, a cardenolide glycoside and a tetrasaccharide derivative.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@]4(C)[C@H]5C[C@@H](O)[C@]6(C)[C@@H](C7=CC(=O)OC7)CC[C@]6(O)[C@@H]5CC[C@@H]4C3)O[C@@H]2C)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](C)O1
Identifiers
PDB—
CAS-ID17598-65-1
RxCUI3248
ChEMBL IDCHEMBL1614
ChEBI ID31468
PubChem CID28620
DrugBankDB01078
UNII IDYGY317RK75 (ChemIDplus, GSRS)
Target
Agency Approved
ATP1A1
ATP1A1
Organism
Homo sapiens
Gene name
ATP1A1
Gene synonyms
NCBI Gene ID
476
Protein name
sodium/potassium-transporting ATPase subunit alpha-1
Protein synonyms
ATPase, Na+/K+ transporting, alpha 1 polypeptide, Na(+)/K(+) ATPase alpha-1 subunit, Na+/K+ ATPase 1, Na, K-ATPase, alpha-A catalytic polypeptide, Na,K-ATPase alpha-1 subunit, Na,K-ATPase catalytic subunit alpha-A protein, Sodium pump subunit alpha-1, sodium-potassium ATPase catalytic subunit alpha-1, sodium-potassium-ATPase, alpha 1 polypeptide
Uniprot ID
Q9UJ21
Mouse ortholog
Atp1a1 (11928)
sodium/potassium-transporting ATPase subunit alpha-1 (Q91Z09)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 279 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details